drugset / Trial / NCT06925659

A Study of QLM2011 in Subjects With Advanced Solid Tumors

NCT06925659

Phase 1 Not yet recruiting 172 enrolled Qilu Pharmaceutical (Hainan) Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The purposeaim of this study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of QLM2011 in patients with advanced solid tumors.

Timeline

Start
2025-05
Primary completion
2026-06
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule Intravenous
Subject QLM2011 Unknown Intravenous

Indications

No indication recorded.